Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances, whereby Vicore Pharma receives gross proceeds of SEK 500 million.

The share issuances were directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is conditional upon approval by an extraordinary general meeting and that a prospectus is published. Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).

Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.

Related

Vinge has advised Gränges on the refinancing of its sustainability-linked credit facility

Vinge has advised Gränges AB (publ) (“Gränges”), a global leader in aluminium rolling and recycling in selected niches, on the refinancing of its sustainability-linked credit facility, which supports Gränges’ sustainability plan.
February 10, 2025

Vinge has advised Priveq Fund VII in connection with a sustainability-linked credit facility

Priveq Fund VII has entered into a credit facility agreement with Swedbank AB (publ) which will primarily be used to finance the fund’s investment activities. The credit facility is linked to certain of Priveq’s sustainability targets, which means that the interest rate on the credit facility will be adjusted up or down based on the performance of Priveq Fund VII's portfolio companies.
February 10, 2025

Vinge advised ReCarber in financing round

Vinge has advised ReCarber AB in its SEK 60 million financing round. The investors included Luminar Ventures, Spintop Ventures and Course Corrected.
February 10, 2025